Form 4: Solesence Director Boosts Stake with Recent Stock Purchases

Sentiment:

Insider Transaction Report 11 December 2025 11:50 AM

📋All filings for Nanophase Technologies CORP

Solesence Director R. Janet Whitmore increased her direct beneficial ownership of common stock through multiple open market purchases in November 2025.

Delay expectedThe filing was delayed due to administrative issues related to establishing Ms. Whitmore's account with Edgar Next.

Better than expectedA director's open market purchases of company stock typically signal confidence in the company's valuation and future prospects, which is generally viewed positively by the market.

Summary

R. Janet Whitmore, a Director of Solesence, Inc. (SLSN), acquired a total of 35,056 shares of common stock through multiple open market purchases between November 14, 2025, and November 19, 2025.
The purchases were made at prices ranging from $1.73 to $1.95 per share.
Following these transactions, Ms. Whitmore's direct beneficial ownership of common stock increased from 2,049,142 shares to 2,084,198 shares.
The filing also details existing derivative securities, including 20,030 shares of deferred common stock and various stock options with exercise prices ranging from $0.61 to $4.17.
The filing was delayed due to administrative issues related to establishing Ms. Whitmore's account with Edgar Next.

Sentiment

Score: 7

Explanation: The director's open market purchases of a significant number of shares indicate strong insider confidence, which is a positive signal. The administrative delay is a minor negative but does not detract significantly from the overall positive sentiment of insider buying.

Positives

A company director, R. Janet Whitmore, increased her direct beneficial ownership of common stock by 35,056 shares, signaling confidence in the company's future.
The purchases were made on the open market, indicating a voluntary investment decision.
The director holds a substantial number of shares, totaling 2,084,198 shares directly, aligning her interests with shareholders.

Negatives

The filing was delayed due to administrative issues, which could indicate minor operational inefficiencies, though specific to the filing process.

Risks

Administrative issues with SEC filing systems (Edgar Next) could potentially lead to delays in public disclosure of insider transactions.

Future Outlook

The filing does not contain specific forward-looking statements or guidance regarding the company's future performance.

Management Comments

The reporting person elected to defer receipt of shares under the Company's Non-Employee Director Deferred Compensation Plan.

Industry Context

This Form 4 filing reflects an individual insider's transaction and does not provide broader industry context or trends. However, insider buying can sometimes be interpreted as a positive signal within the market, suggesting management's confidence in the company's prospects relative to its peers.

Stakeholder Impact

Shareholders: The director's increased stake aligns her interests more closely with other shareholders, potentially boosting investor confidence.

Next Steps

The filing does not explicitly mention future actions or milestones for the company, focusing solely on past insider transactions.

Key Dates

Date	Description
11/17/2016	Date stock options became exercisable for 2,000 shares at $1.85.
12/28/2022	Date stock options became exercisable for 20,000 shares at $4.17.
12/20/2023	Date stock options became exercisable for 13,334 shares at $1.165.
12/27/2024	Date stock options became exercisable for 12,600 shares at $0.61.
11/14/2025	Transaction date for acquisition of 19,789 common shares at $1.73.
11/17/2025	Transaction date for acquisition of 5,000 common shares at $1.87.
11/18/2025	Transaction date for acquisition of 267 common shares at $1.83.
11/19/2025	Transaction date for acquisition of 5,000 common shares at $1.95.
11/19/2025	Transaction date for acquisition of 5,000 common shares at $1.89.
12/11/2025	Signature date of the Form 4 filing.
12/31/2025	Date stock options became exercisable for 12,000 shares at $2.44.
11/17/2026	Expiration date for 2,000 stock options.
12/28/2028	Expiration date for 20,000 stock options.
12/20/2029	Expiration date for 13,334 stock options.
12/27/2030	Expiration date for 12,600 stock options.
12/31/2031	Expiration date for 12,000 stock options.

Recommendation

buy

The director's consistent open market purchases of company stock, increasing her direct beneficial ownership, signals strong confidence in Solesence, Inc.'s future performance and valuation. This insider buying activity, especially from a director, often precedes positive company developments or reflects a belief that the stock is undervalued, making it a compelling 'buy' signal for seasoned investors.

Keywords

Solesence, SLSN, Insider Buying, Form 4, Director Stock Purchase, Equity Acquisition, Beneficial Ownership, Stock Options, Deferred Stock

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.